Boehringer Ingelheim: Plans to invest 33.5 million yuan to establish a subsidiary and has signed a cooperation agreement.

Buchang Pharmaceutical announced that on July 28, 2026, the company's board of directors approved a proposal to invest in the establishment of a holding subsidiary, Shandong Buchang Shengshi Pharmaceutical Co., Ltd., with a registered capital of 50 million yuan. The company will invest 33.5 million yuan to hold a 67% stake. On August 5, 2026, the company officially signed the "Cooperation Agreement on Shandong Buchang Shengshi Pharmaceutical Co., Ltd." with Jinan Fujuchangyuan Enterprise Management Center.